TI-620

N/A

Report date: 2025/01/26 17:20:31

Base Information

Drug NameTI-620
Drug Alias NameUmbilical cord blood-derived Treg cell therapy (Baudax Bio)Umbilical cord blood-derived Treg cell therapy (Teraimmune)TI-620
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunostimulantsRegulatory T-lymphocytes modulators
TargetsUpdating
Therapy Area/IndicationsEczemaDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTeraImmune Inc
China Registration ClassN/A

Develop Information

Active CompaniesBaudax Bio Inc
Inactive CompaniesTeraImmune Inc
Active IndicationsEczemaDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A